ADME pharmacogenetics: current practices and future outlook

Grossman, Iris

doi:10.1517/17425250902902322

Cited by 28 publications

(18 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmacogenomics, genotyping, toxicogenomics, proteomics, metabonimics and metabolomics, chemogenomics, structural biology, chemical systems biology, mapping adverse drug reactions in chemical space, integration and annotation of the data, merging chemical and biological space, generation of drug-target networks, new algorithms, will all play a key role in understanding drug responses in different patients relative to their genetic constitution and in improving the predictive character of in silico methods [151,[356][357][358][359][360][361][362]. New experimental approaches and computer technologies will contribute to this process [67,191,363]. Better understanding of serious adverse drug reactions (SADRs) already allows for the development of the web-hosted tool such as SePreSA [364] http://sepresa.bio-x.cn/.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

In SilicoADME/Tox Predictions

Lagorce

Reynès

Camproux

et al. 2010

ADMET for Medicinal Chemists

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Genetic diversity issues have been reported for this family usually causing decreased or missing enzymatic activity. Gene duplication can occur and lead to increased activity [191]. Thus, it is becoming imperative to recognize individuals who could have such genetic diversities.…”

Section: Metabolismmentioning

confidence: 99%

In SilicoADME/Tox Predictions

Lagorce

Reynès

Camproux

et al. 2010

ADMET for Medicinal Chemists

View full text Add to dashboard Cite

“…T is contrasts with intermediate end points of unclear clinical relevance, such as drug dosing or a biomarker presumed to correlate with e$ cacy. For example, many associations between gene variants and drug metabolism may only have a small impact on clinical outcomes of interest, as exemplif ed by neuropsychiatric pharmacogenetics (39,40).…”

Section: Clinical Trials and Pharmacogenomics: Lessons From Hcv Treatmentioning

confidence: 99%

Pharmacogenetics at 50: Genomic Personalization Comes of Age

Goldstein

2014

Sci. Transl. Med.

View full text Add to dashboard Cite

The study of the genetics of drug responses has a long history but has provided only a few examples of gene variants that are relevant clinically. Here, we discuss the current state of the pharmacogenomics field with emphasis on the potential of data generated through drug development in order to shed new light on genetic variants predictive of therapeutic outcomes-and likewise the potential of pharmacogenomics to improve clinical trial design. We note some examples in which data from clinical trials have already provided clear pharmacogenomic insights and suggest ways in which genomic technology might be used successfully in drug development.

show abstract

“…These studies have been tremendously successful in the sense that for the first time there are epidemiologically robust and statistically sound demonstrations of the effect of these common variants on disease. A remarkable result has been the identification of previously unsuspected pathogenic mechanisms that are likely to provide important avenues for novel interventions and drug development (2, 3). On the other hand, the impact of knowing the specific pattern of variants in individuals is not clear.…”

Section: Common Polymorphisms: Disease Risk Modifiers and Pharmacogenmentioning

confidence: 99%

“Personalizing” academic medicine: opportunities and challenges in implementing genomic profiling

Tweardy

Belmont

2009

Translational Research

View full text Add to dashboard Cite

BCM faculty members spearheaded development of a first generation Personal Genome Profile (Baylor PGP) assay to assist physicians in diagnosing and managing patients in this new era of medicine. The principles that are guiding the design and implementation of the Baylor PGP are high quality, robustness, low expense, flexibility, practical clinical utility and the ability to facilitate broad areas of clinical research. The single most distinctive feature of the approach taken is an emphasis on extensive screening for rare disease causing mutations rather than common risk-increasing polymorphisms. Because these variants have very large direct effects, the ability to inexpensively screen for them could have major immediate clinical impact in disease diagnosis, carrier detection, pre-symptomatic detection of late onset disease and even prenatal diagnosis. In addition to creating a counseling tool for individual ‘consumers’ this system will fit into the established medical record and be used by physicians involved in direct patient care. This paper describes an overall framework for clinical diagnostic array genotyping, and the available technologies as well as highlights the opportunities and challenges for implementation.

show abstract

ADME pharmacogenetics: current practices and future outlook

Cited by 28 publications

References 65 publications

In SilicoADME/Tox Predictions

In SilicoADME/Tox Predictions

Pharmacogenetics at 50: Genomic Personalization Comes of Age

“Personalizing” academic medicine: opportunities and challenges in implementing genomic profiling

Contact Info

Product

Resources

About